Earth Life Sciences Inc (OTCMKTS:CLTS) Stock Consolidates After The Recent Sell-Off

Earth Life Sciences Inc (OTCMKTS:CLTS) stock has been trading in a narrow range over the past weeks after the recent fall. The stock is up 10% over the past month.

Market Action

On Friday, CLTS stock skyrocketed 15.53% to $0.0220. A total of 712K shares traded for the session hands, well above its average volume of 404K shares. The stock opened at $0.0190 and moved in a range of $0.0172 – 0.0220.

Recent News

October 4, 2021 – Earth Life Sciences Enters Immense Healthcare Arena with Acquisition of the VIVA Health Service Platform

Earth Life Sciences announced that it has signed an acquisition agreement with VIVA Health HK Limited, a one-stop smart branded healthcare service, to be implemented in the United States.

The agreement has been finalized and will now enable the Company to enter a rapidly growing healthcare segment of the market and to capitalize on the experience of VIVA Health HK Limited.

Through technical advances such as artificial intelligence and big data, the Viva USA platform optimises the functions of health care staff training management, health care service management and quality control. The customized platform to address American needs will provide services through the mode of online ordering and offline service (“O2O”), the services being a one-stop smart life service branded platform, oriented to the health care industry.

The Company aims to make VIVA USA into a leading one-stop smart life service platform in the United States.

According to, the global healthcare sector will reach $10.059 trillion by 2022. [i] The United States spends significantly more on healthcare, per capita, compared to other nations and such spending is expected to continue growing.

The care of the ever expanding aging population and the development of medical technology have become a huge driving force for the healthcare industry, and the United States will usher in a new era. It is the largest sector in the field of big health. CMS {“Content Management System”} data has shown that national healthcare spending hit a total of $3.8 trillion in the year before the onset of COVID-19. [ii]

The VIVA USA platform will standardize the output of brand images, service processes, service content and training systems, as well as upgrade professional skills and service quality for healthcare service through online and offline learning and assessment.

Key Quote:

“This study elaborates previous published research on the relationship between Tβ4 and sepsis and demonstrates the possible role of Tβ4 in quickly assessing the state of patients entering the ICU with sepsis or sepsis-like symptoms.  Equally important, the study hypothesizes that administering Tβ4 quickly to patients presenting with sepsis, or other systemic infections such as Covid-19, to reduce inflammation and cell death that damages internal organs such as the kidneys may be a viable treatment option,” stated Dr. Allan L. Goldstein, Chairman Emeritus of The Department of Biochemistry and Molecular Medicine at The George Washington University School of Medicine and RegeneRx’s chairman and chief scientific advisor.

Trader Notes:

On the technical basis, CLTS stock is trading well above its 50-day and 20-Day SMA stand at $0.0165 and $0.0194 respectively. Moreover, RSI at 58 signals that the stock is trading near an oversold zone.